Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Respiratory Insufficiency

ClinicalTrials.gov lists 1,861 trials for Respiratory Insufficiency or a narrower condition beneath it. Aerin Medical has the most among industry and government lead sponsors, with 10.

MeSH D012131 Respiratory Tract Diseases C08
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 41 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 80 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 88 Phase 4 Phase 4 86 Not applicable Not applicable 929 Observational Observational 600 Phase 1 Phase 1 41 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 80 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 88 Phase 4 Phase 4 86 Not applicable Not applicable 929 Observational Observational 600

Trials per phase (log scale)

1 more section with rows

1,341 of the 1,861 trials are tagged with Respiratory Insufficiency itself; the rest are tagged with a narrower condition beneath it.

Get the Respiratory Insufficiency report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Respiratory Insufficiency trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 185

1991: 1 trials (Observational 1) 1992: 1 trials (Phase 3 1) 1995: 1 trials (Phase 3 1) 1998: 2 trials (Phase 3 2) 1999: 1 trials (Phase 4 1) 2000: 1 trials (Phase 3 1) 2001: 4 trials (Not applicable 2, Phase 3 1, Phase 1 1) 2002: 11 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2 1, Phase 1/2 1) 2003: 11 trials (Observational 1, Not applicable 5, Phase 4 2, Phase 3 2, Phase 2 1) 2004: 16 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 2) 2005: 19 trials (Observational 3, Not applicable 7, Phase 4 3, Phase 3 5, Phase 2/3 1) 2006: 32 trials (Observational 8, Not applicable 14, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 1 2) 2007: 29 trials (Observational 5, Not applicable 9, Phase 4 4, Phase 3 5, Phase 2 4, Phase 1/2 1, Phase 1 1) 2008: 37 trials (Observational 8, Not applicable 15, Phase 4 4, Phase 3 4, Phase 2 3, Phase 1/2 2, Phase 1 1) 2009: 45 trials (Observational 15, Not applicable 19, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2010: 45 trials (Observational 7, Not applicable 23, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 4) 2011: 72 trials (Observational 21, Not applicable 37, Phase 4 1, Phase 3 4, Phase 2 7, Phase 1 2) 2012: 66 trials (Observational 15, Not applicable 32, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2013: 74 trials (Observational 21, Not applicable 37, Phase 4 4, Phase 3 3, Phase 2 4, Phase 1/2 3, Phase 1 2) 2014: 65 trials (Observational 22, Not applicable 31, Phase 4 5, Phase 3 5, Phase 2 2) 2015: 80 trials (Observational 28, Not applicable 43, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1 1) 2016: 87 trials (Other 1, Observational 27, Not applicable 50, Phase 4 4, Phase 3 1, Phase 2/3 2, Phase 2 1, Phase 1 1) 2017: 82 trials (Other 1, Observational 31, Not applicable 44, Phase 4 3, Phase 3 1, Phase 2 1, Phase 1 1) 2018: 98 trials (Observational 35, Not applicable 57, Phase 4 3, Phase 3 3) 2019: 101 trials (Observational 40, Not applicable 49, Phase 4 5, Phase 3 1, Phase 2/3 1, Phase 1 5) 2020: 185 trials (Observational 65, Not applicable 71, Phase 4 6, Phase 3 13, Phase 2/3 4, Phase 2 21, Phase 1/2 1, Phase 1 4) 2021: 117 trials (Observational 37, Not applicable 58, Phase 4 5, Phase 3 4, Phase 2/3 3, Phase 2 4, Phase 1/2 2, Phase 1 4) 2022: 100 trials (Observational 31, Not applicable 59, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 1) 2023: 124 trials (Observational 40, Not applicable 73, Phase 4 5, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 3) 2024: 133 trials (Observational 48, Not applicable 76, Phase 4 2, Phase 3 4, Phase 2 3) 2025: 112 trials (Observational 45, Not applicable 53, Phase 4 5, Phase 2 6, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 97
2025 112
2024 133
2023 124
2022 100
2021 117
2020 185
2019 101
2018 98
2017 82

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 150 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 1,148 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Respiratory Insufficiency trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 41
Phase 1/2 16
Phase 2 80
Phase 2/3 19
Phase 3 88
Phase 4 86
Not applicable 929
Observational 600
Unknown 2

How many Respiratory Insufficiency trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 96
Recruiting 185
Enrolling by invitation 14
Active, not recruiting 46
Completed 989

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Respiratory Insufficiency trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Aerin Medical 10

Which drugs are being tested for Respiratory Insufficiency? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 13
PROPOFOL 13
Remifentanil 7
FENTANYL 7

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 11
Medicinal gas - oxygen (Nippon Gases 200 bar) 10
mechanical ventilation (MV) 8
Standard Care 5
Salbutamol MDI 5

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Respiratory Insufficiency trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 182 12
Chronic Obstructive Pulmonary Disease 162 2
Cardiac Failure 114 2
Respiratory failure 88 6
Death 65 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Respiratory Insufficiency? (1,862)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. JAMA 2025 Yes
Respiratory Depression Following Intraoperative Methadone: A Retrospective Cohort Study. Anesthesia and analgesia 2025 Yes
Infant feeding and criticality in children. Nursing in critical care 2025 Yes
Quantified Ataxic Breathing Can Detect Opioid-Induced Respiratory Depression Earlier in Normal Volunteers Infused with Remifentanil. Anesthesia and analgesia 2025 Yes
Extracorporeal membrane oxygenation for prevention of barotrauma in patients with respiratory failure: A scoping review. Artificial organs 2025 Yes

Showing 5 of 1,862 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages